Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESMO 2019 | Onvansertib with cytarabine or decitabine for R/R AML

Amer Zeidan • 27 Sep 2019
ESMO 2019
Acute Myeloid Leukemia Leukemia Cytarabine Decitabine Onvansertib

Amer Zeidan, MBBS, MHS, Yale Cancer Center, New Haven, CT, talks about the polo-like kinase 1 (PLK1) inhibitor onvansertib in combination with low-dose cytarabine or decitabine in R/R acute myeloid leukaemia (AML). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Amer Zeidan

iwMDS wrap-up: translating research into practice to optimize patient care 23:22
iwMDS wrap-up: translating research into practice to optimize patient care
Amer Zeidan et al. • 29 Jun 2025
An update on immune checkpoint inhibition in MDS & AML: investigating sabatolimab and bexmarilimab 2:40
An update on immune checkpoint inhibition in MDS & AML: investigating sabatolimab and bexmarilimab
Amer Zeidan • 12 Jun 2025
Combining ziftomenib with chemotherapy for the treatment of AML: the KOMET trials 2:43
Combining ziftomenib with chemotherapy for the treatment of AML: the KOMET trials
Amer Zeidan • 12 Jun 2025
Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS
Amer Zeidan et al. • 18 May 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals